Industry Newsbase editinggene therapybeam therapeuticsstrategic financing
Beam Therapeutics Raises Financing, Targets BLA Submission
5.1
Beam Therapeutics Inc. reported fiscal Q4 and full-year 2025 results on Feb. 24, announced a new BEAM-304 program for phenylketonuria, and said it targets a BLA submission this year for a sickle cell therapy. On Feb. 25, RBC raised the price target to $26, and the company secured long-term non-dilutive financing from Sixth Street with $1.25 billion cash on hand.
Key Points
- 1Reports $1.25 billion cash and Q4/FY2025 results, plus new BEAM-304 PKU program
- 2Secures long-term non-dilutive Sixth Street financing to support potential risto-cel commercialization
- 3Targets BLA submission this year for sickle cell, advancing pivotal BEAM-302 development path
Scoring Rationale
Official Q4 results and strategic financing raise credibility and execution prospects, but biotech focus limits broader data-science relevance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
